Enliven Therapeutics, Inc. · NASDAQ:ELVN

Hohl Benjamin sold 6,018 Enliven Therapeutics, Inc. shares (Form 4)

Traded Aug 17, 2026 · Filed Aug 19, 2026

On Aug 17, 2026, Hohl Benjamin (CHIEF FINANCIAL OFFICER) sold 6,018 Enliven Therapeutics, Inc. shares at an average US$58.58 for US$353K under a trading plan, leaving 40,036 shares. Filed Aug 19, 2026 (Form 4).

Sold
6,018 shares
Price
US$58.58 average (US$58.35 to US$59.35)
Value
US$353K
Holding after
40,036 shares
Trading plan
Yes (Made under a plan set in advance)
Role
CHIEF FINANCIAL OFFICER

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Aug 17, 2026Common StockSale4,630US$58.3541,424Direct
Aug 17, 2026Common StockSale1,388US$59.3540,036Direct

Source

View original at SEC

Related